Mumbai, Nov. 13 -- EBITDA fell by 14.86% to Rs 32.66 crore in Q2 FY26 from Rs 38.35 crore in Q2 FY25.

Profit before tax in Q2 FY26 stood at Rs 28.81 crore, down by 17.17% from Rs 34.78 crore recorded in Q2 FY25.

Lincoln Pharmaceuticals stated that the company is targeting a revenue of Rs 1,000 crore within the next three years, driven by business expansion into high-value product lines and entry into new markets. This goal is part of a broader strategy to achieve a 15-18% annual growth rate, driven by strong performance in the cardiac, diabetic, dermatology, and ENT segments.

Mahendra Patel, managing director, Lincoln Pharmaceuticals, said: "We are pleased to report another strong quarter, reflecting our continued focus on sustainable ...